Otezla Now Available for Kids With Moderate to Severe Psoriasis

August 20, 2024

Just Published: NPF’s Psoriasis Health Indicator Report

August 16, 2024

Scratching Beneath the Surface: Seven Ways to Elevate Conversations With Patients About Their Skin Conditions

August 9, 2024

FDA Approves Alembic’s Generic Acitretin Capsules for Psoriasis

August 7, 2024

NPF Launches Annual Take ACTION Campaign for Psoriasis Action Month

August 6, 2024

PsO Pipeline Watch: Alumis Initiates Phase 3 Clinical Program Evaluating Its Oral TYK2 Inhibitor in Moderate-to-Severe Plaque PsO

July 29, 2024

Walmart Expands Autoimmune-Focused Care to 25 More Pharmacies Across Five States

July 25, 2024

Arcutis Submits sNDA to FDA for ZORYVE Foam 0.3% for Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Older

July 23, 2024

Scinai’s Intralesional Anti-IL-17 NanoAb Shows Early Promise in Mild to Moderate PsO

July 15, 2024

Inside Sun Pharma’s I LUV YA for The Long Haul PsO Campaign

July 13, 2024

Risankizumab Bests Other Biologics in Real-world Psoriasis Study

July 2, 2024

Will Blocking FABP5 Help Treat Psoriasis?

July 2, 2024